Role of K-ras mutation analysis in EUS-FNA samples obtained from pancreatic solid mass

Journal of Clinical Gastroenterology

Volumn 49, Issue 2, 2015, Pages 173-

  Matsubayashi, Hiroyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY; K RAS PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ONCOPROTEIN; RAS PROTEIN;

ASSAY; CANCER PROGNOSIS; CARCINOGENESIS; DIAGNOSTIC ACCURACY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC ULTRASONOGRAPHY GUIDED FINE NEEDLE ASPIRATION; FINE NEEDLE ASPIRATION BIOPSY; GENE; GENE MUTATION; GENOTYPE; HUMAN; KRAS GENE; LETTER; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; FEMALE; GENETICS; MALE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84921540608     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000192     Document Type: Letter

References (10)

1. Bournet B, Selves J, Grand D, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. J Clin Gastro-enterol. 2015;49:50-56.
2. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008; 1:306-316.
3. Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer. 2001;84: 253-262.
4. Matsubayashi H, Watanabe H, Nishikura K, et al. Determination of pancreatic ductal carcinoma histogene-sis by analysis of mucous quality and K-ras mutation. Cancer. 1998;82:651-660.
5. Matsubayashi H, Watanabe H, Ajioka Y, et al. Different amounts of K-ras mutant epithelial cells in pancreatic carcinoma and mass-forming pancreatitis. Pancreas. 2000;21:77-85.
6. Fuccio L, Hassan C, Laterza L, et al. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-Analysis of prospective studies. Gastrointest Endosc. 2013;78: 596-608.
7. Heinemann V, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut. 2013; 62:751-759.
8. Ogura T, Yamao K, Hara K, et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresect-Able pancreatic cancer. J Gastroenterol. 2013;48:640-646.
9. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol. 2013;31: 1112-1121.
10. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.